Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Xylem, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Xylem, Inc. trades at $120.88 (market cap $28.81B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Xylem, Inc. pays a 1.42% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | XYL | |
|---|---|---|
Market Cap | $39.89B | $28.81B |
Sector | Health | Industrials |
52-Week High | $491.22 | $152.95 |
52-Week Low | $278.09 | $106.34 |
Enterprise Value | $38.15B | $30.07B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
XYL trades at $121.22, up 1.96% with a bullish technical outlook. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.12 exceeding expectations. Revenue grew to $9.04B in 2025, and net income margin improved to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing growth in water technology solutions. The company maintains a strong balance sheet with total assets of $16.49B and shareholder equity of $10.64B as of 2024.
XYL presents a favorable investment case with analyst consensus price target of $153.14, implying 26% upside. Strengths include steady revenue growth, expanding margins, and positive cash flow trends. Risks involve market volatility and execution challenges in scaling new partnerships. Institutional sentiment is mixed but leans bullish, supported by a 47.5% buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
